Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
about
Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.Neoadjuvant therapy before surgical treatmentAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Targeted survival improvements in clinical trials: are you an absolutist or relativist?Liver-directed conversion therapy in metastatic colon cancer.Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis.The Globalization of Cooperative Groups.Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Plasma angiopoietin-2 is persistently elevated after non-small cell lung cancer surgery and stimulates angiogenesis in vitro.Update on Anti-Angiogenesis Therapy in Colorectal Cancer.Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.Current opinion on optimal treatment for colorectal cancer.Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer.Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.Ten years of anti-vascular endothelial growth factor therapy.Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer.
P2860
Q30248296-35E39147-D710-4814-A6D9-A1F470380858Q30249335-C5BFD320-9F02-4D96-96FE-FBC6A1E94D7DQ30625567-ACC5F311-4472-4680-884F-FC5781CF93F8Q31168985-C3990AD2-7894-4073-9937-46754584A011Q33697924-AFF9F517-BC15-49AF-BDAB-E264E5F3FD85Q33770680-E12B3112-1296-4D4D-81A2-F32F2831E4ACQ33928010-BF11F440-E071-4358-92F8-08E655D74031Q34648886-FA5D37A0-EB71-4E14-967C-3977ED597C4CQ35084155-C99C8B82-870F-4633-A1D4-D726BB5C66F4Q35419309-373DA9AC-A5CC-4D74-AE3B-346CB729BC98Q35817933-2A19C6C8-6688-4E03-B0C1-514520EF2749Q36118410-25212BA6-4101-42F1-9394-7CE7F045FD2CQ36119749-E20C058E-6963-4D05-929B-A7D4B9BAD62CQ36813582-460BEC9E-7D17-403D-9675-45E87D2E4038Q36913538-089E36A4-C913-41C8-AB01-727162C56A22Q36932216-5735EF68-94DE-41E3-A264-F6DA478CF653Q37015715-34B5E2D4-32AC-4CDA-8A52-3057FDD5AE5FQ37175995-F439A869-E60E-4405-9825-A0D55FD97E5CQ37190578-2BEE9EF9-7069-4A0D-AF54-D7E699BD6183Q37236229-EC35DCE7-3BE6-44DB-87D2-E34B3D1B2CF8Q37358002-4BD4BB53-9749-48A5-8728-3D24FDB9154EQ37411781-43E1E7E8-96AB-45D9-A3E1-17F14305231AQ37496645-6CD5A21A-1184-44A3-B2BF-EDB83330C5B5Q37562355-708487AC-9A3C-468B-ABFE-011382147A4FQ37587441-37148EA2-5B6B-41EA-B297-5332F0522B86Q38101612-4E104BBE-8FC6-4ABC-A14F-6304519881E4Q38383214-7D98D4A6-83C0-47BA-993B-A583131CDA2CQ38431573-CED22DFA-CF65-4D50-9095-176540065C64Q38648300-F6D80C94-4662-43B1-BCAE-0901980DAEE3Q38707832-266E5B6B-8AF0-4F3C-966B-A6A6FD2167F8Q38786707-4E3CE62A-EF7B-4F3A-8CFE-F81763AA188EQ38787244-49F693BF-BBEF-4617-8645-AA4A0C2B8AD7Q38981326-4EE1AB32-0A5D-422C-9E07-6174DC931B11Q39204706-16029852-A7EF-4AFB-A095-4494496EEAAAQ41612851-CAEA2381-B18B-435B-85F7-37CC24356215Q41697688-1D7600E7-1A76-4F1F-B721-C619792DA3F1Q42067472-D973C710-B386-49B0-AEB6-9CA47FD8EBA6Q43967231-BE888BB4-2728-4E4A-8A41-3886E34F0A0EQ46407140-2B5CCA97-8D03-43EA-B87F-71BC03F7BAC4Q47131106-1D22B2D3-4C48-477E-A6C1-9F2330FCBC78
P2860
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@en
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@nl
type
label
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@en
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@nl
prefLabel
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@en
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@nl
P2093
P2860
P356
P1476
Bevacizumab in stage II-III co ...... and Bowel Project C-08 trial.
@en
P2093
Carmen J Allegra
Greg Yothers
Michael J O'Connell
Nicholas J Petrelli
Norman Wolmark
Saima Sharif
Samia H Lopa
P2860
P304
P356
10.1200/JCO.2012.44.4711
P407
P577
2012-12-10T00:00:00Z